home / stock / esalf / esalf quote
Last: | $42.84 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $42.84 |
High: | $0 |
Low: | $0 |
Volume: | 52 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$42.84 | $0 | $42.84 | $0 | $0 | 52 | 05-16-2024 |
$42.84 | $0 | $42.84 | $0 | $0 | 5,283 | 05-15-2024 |
$42.84 | $43.655 | $42.84 | $43.655 | $42.54 | 362 | 05-14-2024 |
$44.67 | $44.67 | $44.67 | $44.67 | $44.67 | 167 | 05-13-2024 |
$42.55 | $0 | $42.55 | $0 | $0 | 400 | 05-10-2024 |
$42.55 | $0 | $42.55 | $0 | $0 | 2 | 05-09-2024 |
$42.55 | $0 | $42.55 | $0 | $0 | 608 | 05-07-2024 |
$42.55 | $42.585 | $42.55 | $42.585 | $42.55 | 925 | 05-06-2024 |
$43.67 | $42.945 | $43.67 | $43.67 | $42.945 | 1,330 | 05-03-2024 |
$42.12 | $0 | $42.12 | $0 | $0 | 5 | 05-02-2024 |
$42.12 | $42.12 | $42.12 | $42.12 | $42.12 | 190 | 05-01-2024 |
$40.82 | $0 | $40.82 | $0 | $0 | 45 | 04-30-2024 |
$40.82 | $40.82 | $40.82 | $40.82 | $40.82 | 177 | 04-29-2024 |
$40.005 | $0 | $40.005 | $0 | $0 | 4 | 04-26-2024 |
$40.005 | $40.005 | $40.005 | $40.005 | $40.005 | 310 | 04-25-2024 |
$40.1 | $40.31 | $40.1 | $41.12 | $40.1 | 31,467 | 04-24-2024 |
$38.71 | $38.71 | $38.71 | $38.71 | $38.71 | 570 | 04-22-2024 |
$38.95 | $38.79 | $38.95 | $38.95 | $38.79 | 925 | 04-19-2024 |
$37.53 | $38.1 | $37.53 | $38.1 | $37.53 | 2,125 | 04-18-2024 |
$38.11 | $38.18 | $38.11 | $38.18 | $38.11 | 899 | 04-17-2024 |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status TOKYO and CAMBRIDGE, Mass., May 15, 2024 - (JCN Newswire) - Eisai Co., Ltd. and...
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures TOKYO, May 13, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house disc...
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...